Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
Halozyme Therapeutics, Inc. (HALO) had Consolidated Net Income/Loss of $150.05M for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
$376.71M |
|
$150.05M |
|
$79.24M |
|
$297.47M |
|
$192.19M |
|
$184.52M |
|
$-4.19M |
|
$180.33M |
|
$180.33M |
|
$150.05M |
|
$150.05M |
|
|
Consolidated Net Income/Loss |
$150.05M |
$150.05M |
|
$184.52M |
|
$220.47M |
|
118.14M |
|
122.88M |
|
$1.27 |
|
$1.22 |
|
| Balance Sheet Financials | |
$1.00B |
|
$82.23M |
|
$1.67B |
|
$2.67B |
|
$363.21M |
|
$1.94B |
|
$2.09B |
|
$2.45B |
|
$219.64M |
|
$-1.31B |
|
$219.64M |
|
118.52M |
|
| Cash Flow Statement Financials | |
$180.08M |
|
$-2.88M |
|
$-1.61M |
|
$136.42M |
|
$312.01M |
|
$175.59M |
|
$16.64M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.76 |
|
-- |
|
-- |
|
0.90 |
|
9.76 |
|
78.97% |
|
48.98% |
|
48.98% |
|
-- |
|
47.87% |
|
39.83% |
|
$176.34M |
|
-- |
|
-- |
|
-- |
|
0.14 |
|
0.51 |
|
0.82 |
|
109.42 |
|
68.32% |
|
-11.41% |
|
5.61% |
|
6.96% |
|
$1.85 |
|
$1.44 |
|
$1.47 |
|